JPRN-jRCT2080222909未知2 期
Phase II clinical study of CIM331 in hemodialysis patients with pruritus.
CHUGAI PHARMACEUTICAL CO., LTD0 个研究点目标入组 60 人开始时间: 2015年7月9日最近更新:
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •(1) Patients who receive hemodialysis three times a week.
- •(2) Patients who have been treated with systemic therapy or topical therapy for pruritus and who are inadequately controlled by them, or patients who have been treated with nalfurafine hydrochloride for pruritus.
排除标准
- •Patients who are judged to be inadequate for this study participation by investigator.
研究者
相似试验
已完成
3 期
A phase III clinical study of MR13A9 in hemodialysis patients with pruritusJPRN-jRCT2011200021Shimizu Yoshitaka172
已完成
3 期
A Phase III Study of PA21 in Hemodialysis Patients With HyperphosphatemiaHemodialysisHyperphosphatemiaNCT01850602Kissei Pharmaceutical Co., Ltd.213
已完成
不适用
A clinical study for FS-311(hemodiafilter)Renal failureJPRN-UMIN000018858Toray Industries,Inc.14
进行中（未招募）
1 期
Gene therapy for WASWiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency caused by mutations in a single gene ,the Wiskott-Aldrich Syndrome Protein (WASP). WAS is characterised by micro-thrombocytopenia, recurrent infections,eczema and associated with a high incidence of auto-immunity and of lymphoid malignancies. Over 150 unique mutations in the WAS gene have been identified.Loss-of-function mutations in this gene have widespread consequences on hematopoietic lineages.MedDRA version: 19.1Level: PTClassification code 10047992Term: Wiskott-Aldrich syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2007-004308-11-GBGenethon
已完成
3 期
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)AnaemiaNCT03400033GlaxoSmithKline407